Clinical Trial Update: Phase III Insulin Add-On Asia Regional Program - ST [Phase 3]

View source ↗

Summary

A Phase III insulin add-on program in Asia under the AstraZeneca umbrella has completed enrollment, with results posted in March 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• Insulin (insulin)

Snippet

Sponsor: AstraZeneca | Conditions: Diabetes | Phase 3 | Status: COMPLETED | Results posted: 2017-03-06